Enhanced Membranes for Active Mixing Oxygenators

用于主动混合充氧器的增强型膜

• 批准号: 6403910
• 负责人: NINA M Lamba-Kohli
• 金额: $ 11万
• 依托单位: COMPACT MEMBRANE SYSTEMS, INC.
• 依托单位国家: 美国
• 财政年份: 2001
• 资助国家: 美国
• 起止时间: 2001-09-30 至 2003-03-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/6403910
• 关键词: artificial membranes; biomedical equipment development; blood oxygenator; carbon dioxide transport; cow; fluid flow; oxygen transport; respiratory gas transport; surface coating

Historically blood oxygenators for short-term by-pass surgery or newly developing long-term strategies use systems that are liquid side mass transfer, limited. Long-term therapies require non-porous coatings to limit blood oxygenator wet out. Design advances led to improved fluid dynamics which enhanced mass transfer. In these later systems membrane transport limitations now are major limitations. Compact Membrane Systems (CMS) developed non-porous membranes for long-term blood oxygenation. This CMS first generation blood oxygenation technology produces membranes with 150 cc/min-m2 oxygen transport. With more compact second generation systems there is need for higher flux non-porous membranes. CMS has identified novel routes to improve membrane oxygen transport ten-fold. This improvement in oxygen transport should be sufficient to meet need of improved fluid dynamics second generation products. These new systems should also significantly improve fabrication economics. In Phase I CMS will develop membranes for blood oxygenation with a five-fold improvement in flux. These novel membranes will demonstrate improved fluid dynamics and significantly enhance overall system performance. Animal studies with detailed methodology are included in this program. Membrane integrity will be verified at the end of the tests. PROPOSED COMMERCIAL APPLICATIONS: This technology will broadly enhance the capability for both long-term and short-term blood gas exchange. Therefore it should be of value for long-term treatments for ARDS, ECMO and artificial lung as well as conventional by-pass surgery.

历史上，用于短期旁路手术或新开发的长期策略的血液氧合器使用液体侧传质有限的系统。长期治疗需要无孔涂层来限制血液氧合器的润湿。设计的进步导致流体动力学的改进，从而增强了传质。在这些后来的系统中，膜运输限制现在是主要的限制。紧凑型膜系统（CMS）开发了用于长期血液氧合的无孔膜。这种CMS第一代血液氧合技术生产的膜具有150 cc/min-m2的氧传输。对于更紧凑的第二代系统，需要更高通量的无孔膜。CMS已经确定了将膜氧转运提高十倍的新途径。氧输送的这种改进应足以满足改进的流体动力学第二代产品的需要。这些新系统还将显著提高制造经济性。在第一阶段，CMS将开发用于血液氧合的膜，其通量提高了五倍。这些新型膜将展示出改进的流体动力学，并显着提高整体系统性能。本计划包括详细方法学的动物研究。将在试验结束时验证膜完整性。拟议的商业应用：该技术将广泛增强长期和短期血气交换的能力。因此，对于ARDS的长期治疗、ECMO和人工肺以及常规的旁路手术都有价值。